Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Pasithea Therapeutics Corp.

Get SEC filing alerts via email and in your feed for Pasithea Therapeutics Corp.

KTTA KTTAW

Pasithea Therapeutics Corp.

About Pasithea Therapeutics Corp.

Pasithea Therapeutics is a biotech company focused on developing innovative treatments for CNS disorders, RASopathies, and cancers. Its pipeline includes next-generation MEK inhibitors, monoclonal antibodies for ALS, and small molecules for schizophrenia. The company emphasizes targeted therapies with improved safety, efficacy, and dosing profiles, leveraging proprietary drug design and strategic collaborations to address high unmet medical needs in neurology and oncology markets.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Pasithea Therapeutics Corp.

1
1
Pasithea Therapeutics Corp. Pasithea Therapeutics Reports Q1 2026 Financial Results with $2.87M Net Loss

Via official filing (AI summary) | 19 days ago | 0 comments

2
1
Pasithea Therapeutics Corp. Pasithea Therapeutics Reports $20.4 Million Net Loss for 2025, Accumulated Deficit Reaches $70 Million

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Pasithea Therapeutics Corp. Pasithea Therapeutics Reports Q3 2025 Financial Results with $3.04 Million Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Pasithea Therapeutics Corp. Pasithea Therapeutics Reports Q2 2025 Financial Results with Reduced Net Loss

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Pasithea Therapeutics Corp. Pasithea Therapeutics Reports Q1 2025 Financial Results with $3.56 Million Net Loss

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Pasithea Therapeutics Corp. Pasithea Therapeutics Reports $13.9 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Pasithea Therapeutics Corp. Pasithea Therapeutics Reports Mixed Financial Results, Decrease in Cash Reserves, and Strategic Developments

Via official filing (AI summary) | over 1 year ago | 0 comments